Prospective screening for monkeypox infection among users of HIV pre-exposure prophylaxis in Denmark

被引：2

作者：

Thomassen, Sofie Ellen ^{[1
]}

von Schreeb, Sebastian ^{[1
,2
]}

Kirkby, Nikolai Soren ^{[3
]}

Pinholt, Mette ^{[4
]}

Lebech, Anne-Mette ^{[5
,6
]}

Kronborg, Gitte ^{[1
,6
]}

Engsig, Frederik Neess ^{[1
]}

机构：

[1] Copenhagen Univ Hosp Amager & Hvidovre, Dept Infect Dis, Copenhagen, Denmark

[2] Statens Serum Inst, Infect Dis Epidemiol & Prevent, Copenhagen, Denmark

[3] Copenhagen Univ Hosp, Rigshospitalet, Dept Clin Microbiol, Copenhagen, Denmark

[4] Copenhagen Univ Hosp Amager & Hvidovre, Dept Clin Microbiol, Copenhagen, Denmark

[5] Copenhagen Univ Hosp, Rigshospitalet, Dept Infect Dis, Copenhagen, Denmark

[6] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 2024年 / 35卷 / 05期

关键词：

Monkeypox; screening; asymptomatic; pre-exposure prophylaxis; HIV pre-exposure prophylaxis; vaccine; vaccination;

D O I：

10.1177/09564624231223764

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction: During the 2022 outbreak of mpox (previously called monkeypox), which primarily affected Gay, Bisexual, and other Men who have Sex with Men (GBMSM), testing was mainly limited to individuals with symptoms of infection. Although sporadic cases of mpox continue to be diagnosed in Denmark, the feasibility of screening asymptomatic high-risk populations, such as those using HIV pre-exposure prophylaxis (PrEP), is still unknown. Methods: During the autumn of 2022, a rectal swab test for mpox PCR was included in the routine sexually transmitted infections (STI) screening for PrEP users. Results: The screening included 224 asymptomatic men with a median age of 36.5 years. One patient (0.4%) tested positive for mpox. Ten (4.5%) and nine (4.0%) had chlamydia and gonorrhea, respectively. Discussion: Our study demonstrates that screening for mpox is feasible in two Danish PrEP clinics.

引用

页码：374 / 378

页数：5

共 50 条

[41] Pre-Exposure Prophylaxis for HIV Upfront
de Mendoza, Carmen
AIDS REVIEWS, 2011, 13 (01) : 57 - 58
[42] Pre-Exposure Prophylaxis and HIV Incidence
Mann, Samuel
B E JOURNAL OF ECONOMIC ANALYSIS & POLICY, 2023, 23 (04): : 1163 - 1173
[43] Prescribing pre-exposure prophylaxis for HIV
Bloch, Mark
AUSTRALIAN PRESCRIBER, 2020, 43 (06) : 200 - 203
[44] HIV moments and pre-exposure prophylaxis
Grant, Robert M.
Glidden, David V.
LANCET, 2016, 387 (10027): : 1507 - 1508
[45] Modeling HIV Pre-Exposure Prophylaxis
Straubinger, Thomas
Kay, Katherine
Bies, Robert
FRONTIERS IN PHARMACOLOGY, 2020, 10
[46] HIV pre-exposure prophylaxis (PrEP)
Tumarkin, Ethan
Siedner, Mark J.
Bogoch, Isaac I.
BMJ-BRITISH MEDICAL JOURNAL, 2019, 364
[47] Pre-exposure prophylaxis to HIV in practice
Buxeraud, Jacques
ACTUALITES PHARMACEUTIQUES, 2016, 55 (554): : 8 - 8
[48] HIV pre-exposure prophylaxis in women
Haberl A.
MMW - Fortschritte der Medizin, 2017, 159 (Suppl 2) : 42 - 44
[49] Updates in pre-exposure prophylaxis for HIV
Mushtaq, Ammara
Kazi, Farooq
LANCET INFECTIOUS DISEASES, 2022, 22 (03): : 320 - 320
[50] SEXUALLY TRANSMITTED INFECTION DIAGNOSES AMONG HIV PRE-EXPOSURE PROPHYLAXIS USERS LARGELY EXPLAINED BY PARTNER NUMBERS AND TESTING FREQUENCY
Marcus, U.
Schink, S.
Maass, J.
Weber, C.
SEXUALLY TRANSMITTED INFECTIONS, 2021, 97 : A103 - A103

← 1 2 3 4 5 →